Elizabeth A. Bartlett
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elizabeth A. Bartlett has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Francesca Zanderigo
New York State Psychiatric Institute
6 shared publications - Christine DeLorenzo
Stony Brook University
5 shared publications R Todd Ogden
Molecular Imaging and Neuropathology Area, New York State Psychiatric Institute, New York, New York
5 shared publicationsJ John Mann
New York State Psychiatric Institute
4 shared publicationsRamin V. Parsey
Department of Psychiatry, Stony Brook Medicine, Stony Brook, NY11794, USA
4 shared publicationsFrancesca Zanderigo
Molecular Imaging and Neuropathology Area, New York State Psychiatric Institute, New York, USA
3 shared publications
Latest Publications
- 26 October 2026
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 71 (20) , 205026
Cross-scanner validation and time-stability analysis of STARE, a blood-free quantification tool for brain imaging with irreversible PET tracers
Objective . ‘Gold standard’ blood-based quantification of dynamic 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET) data has limited practical clinical applications due to cost and complexity of data collection and analysis. We previously presented a blood-free quantification alternative, STARE (source-to-target automatic rotating estimation), that was validated on 18 F-FDG data acquired on an ECAT EXACT HR+ scanner. Here, we extend that initial work by applying STARE to within-subject data acquired with both a Siemens Biograph mCT scanner and a portable Brain Biosciences CerePET scanner. Approach . Performance was assessed by comparing regional net influx rates ( K i ) estimated using STARE and the standard blood-based Patlak approach. Twenty participants underwent 60 min brain 18 F-FDG scans, on two different days, once in each scanner. The time-stability of both STARE- and Patlak-based K i estimates was evaluated by applying each method to the first 20 (STARE only), 30, 40, and 50 min of data. Main results . STARE demonstrated high correlation with Patlak K i estimates, particularly in the Biograph mCT ( r = 0.82–0.93 (within-region)), with lower correlation in the CerePET ( r = 0.27–0.62 (within-region)). In the Biograph dataset, STARE showed small deviations from the 60 min estimates across all evaluated durations (20 min and above), whereas deviations increased with shorter durations in CerePET data. The Patlak approach showed smaller changes across abbreviated scan durations in both datasets. Significance . STARE shows potential as a noninvasive alternative to traditional blood-based quantification of dynamic 18 F-FDG PET brain data, facilitating shorter, blood-free acquisition. This advancement could make dynamic 18 F-FDG PET brain imaging more accessible and comfortable for patients, potentially facilitating broader clinical adoption.
- 26 October 2026
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 71 (20) , 205026
Cross-scanner validation and time-stability analysis of STARE, a blood-free quantification tool for brain imaging with irreversible PET tracers
Objective . ‘Gold standard’ blood-based quantification of dynamic 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET) data has limited practical clinical applications due to cost and complexity of data collection and analysis. We previously presented a blood-free quantification alternative, STARE (source-to-target automatic rotating estimation), that was validated on 18 F-FDG data acquired on an ECAT EXACT HR+ scanner. Here, we extend that initial work by applying STARE to within-subject data acquired with both a Siemens Biograph mCT scanner and a portable Brain Biosciences CerePET scanner. Approach . Performance was assessed by comparing regional net influx rates ( K i ) estimated using STARE and the standard blood-based Patlak approach. Twenty participants underwent 60 min brain 18 F-FDG scans, on two different days, once in each scanner. The time-stability of both STARE- and Patlak-based K i estimates was evaluated by applying each method to the first 20 (STARE only), 30, 40, and 50 min of data. Main results . STARE demonstrated high correlation with Patlak K i estimates, particularly in the Biograph mCT ( r = 0.82–0.93 (within-region)), with lower correlation in the CerePET ( r = 0.27–0.62 (within-region)). In the Biograph dataset, STARE showed small deviations from the 60 min estimates across all evaluated durations (20 min and above), whereas deviations increased with shorter durations in CerePET data. The Patlak approach showed smaller changes across abbreviated scan durations in both datasets. Significance . STARE shows potential as a noninvasive alternative to traditional blood-based quantification of dynamic 18 F-FDG PET brain data, facilitating shorter, blood-free acquisition. This advancement could make dynamic 18 F-FDG PET brain imaging more accessible and comfortable for patients, potentially facilitating broader clinical adoption.
- Open Access
- 29 June 2026
- Published by Elsevier in Biological Psychiatry
- Vol. 100 (10) , 1045-1054
Kappa opioid receptor availability in borderline personality disorder: An in-vivo investigation with [11C]EKAP PET imaging
- 29 June 2026
- Published by Elsevier in Biological Psychiatry
- Vol. 100 (10) , 1045-1054
Open AccessKappa opioid receptor availability in borderline personality disorder: An in-vivo investigation with [11C]EKAP PET imaging
- Open Access
External validation and time-stability analysis of STARE, a blood-free quantification tool for irreversible PET tracers
Rationale: “Gold standard” blood-based quantification of dynamic 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET) data has limited practical clinical applications due to cost and complexity of data collection and analysis. We previously presented a blood-free quantification alternative, STARE (Source-to-Target Automatic Rotating Estimation), that was validated on 18 F-FDG data acquired on a ECAT EXACT HR+ scanner. Here, we extend that initial work by externally validating STARE using within-subject data acquired with both a Siemens Biograph mCT scanner and a portable Brain Biosciences CerePET scanner. Methods: Performance was assessed by comparing regional net influx rates (K i ) estimated using STARE and the standard blood-based Patlak approach. Twenty participants underwent 60-minute 18 F-FDG scans, on two different days, once in each scanner. The time-stability of both STARE- and Patlak-based K i estimates was evaluated by applying each method to the first 20 (STARE only), 30, 40, and 50 minutes of data. Results: STARE demonstrated high correlation with Patlak K i estimates across both scanner types, particularly in the Biograph mCT ( r = 0.93), with lower correlation in the CerePET ( r = 0.71). In the Biograph dataset, STARE provided reliable K i estimates at all evaluated scan durations (20 minutes and above), while in the CerePET dataset, only the 50-minute duration yielded STARE K i estimates that were not significantly different from the full 60 minutes. The Patlak approach provided K i estimates at 40 minutes scan duration and above that did not differ from the 60-min scan results in both datasets. Conclusion: STARE is a viable, noninvasive alternative to traditional blood-based quantification of dynamic 18 F-FDG PET data, facilitating shorter, blood-free acquisition. This advancement could make dynamic 18 F-FDG PET imaging more accessible and comfortable for patients, promoting broader clinical adoption.
Open AccessExternal validation and time-stability analysis of STARE, a blood-free quantification tool for irreversible PET tracers
Rationale: “Gold standard” blood-based quantification of dynamic 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET) data has limited practical clinical applications due to cost and complexity of data collection and analysis. We previously presented a blood-free quantification alternative, STARE (Source-to-Target Automatic Rotating Estimation), that was validated on 18 F-FDG data acquired on a ECAT EXACT HR+ scanner. Here, we extend that initial work by externally validating STARE using within-subject data acquired with both a Siemens Biograph mCT scanner and a portable Brain Biosciences CerePET scanner. Methods: Performance was assessed by comparing regional net influx rates (K i ) estimated using STARE and the standard blood-based Patlak approach. Twenty participants underwent 60-minute 18 F-FDG scans, on two different days, once in each scanner. The time-stability of both STARE- and Patlak-based K i estimates was evaluated by applying each method to the first 20 (STARE only), 30, 40, and 50 minutes of data. Results: STARE demonstrated high correlation with Patlak K i estimates across both scanner types, particularly in the Biograph mCT ( r = 0.93), with lower correlation in the CerePET ( r = 0.71). In the Biograph dataset, STARE provided reliable K i estimates at all evaluated scan durations (20 minutes and above), while in the CerePET dataset, only the 50-minute duration yielded STARE K i estimates that were not significantly different from the full 60 minutes. The Patlak approach provided K i estimates at 40 minutes scan duration and above that did not differ from the 60-min scan results in both datasets. Conclusion: STARE is a viable, noninvasive alternative to traditional blood-based quantification of dynamic 18 F-FDG PET data, facilitating shorter, blood-free acquisition. This advancement could make dynamic 18 F-FDG PET imaging more accessible and comfortable for patients, promoting broader clinical adoption.
- Open Access
- 24 January 2023
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 66 (1) , 1-21
In vivo serotonin 1A receptor hippocampal binding potential in depression and reported childhood adversity
Background: Reported childhood adversity (CA) is associated with development of depression in adulthood and predicts a more severe course of illness. Although elevated serotonin 1A receptor (5-HT1AR) binding potential, especially in the raphe nuclei, has been shown to be a trait associated with major depression, we did not replicate this finding in an independent sample using the partial agonist positron emission tomography tracer [11C]CUMI-101. Evidence suggests that CA can induce long-lasting changes in expression of 5-HT1AR, and thus, a history of CA may explain the disparate findings. Methods: Following up on our initial report, 28 unmedicated participants in a current depressive episode (bipolar n = 16, unipolar n = 12) and 19 non-depressed healthy volunteers (HVs) underwent [11C]CUMI-101 imaging to quantify 5-HT1AR binding potential. Participants in a depressive episode were stratified into mild/moderate and severe CA groups via the Childhood Trauma Questionnaire. We hypothesized higher hippocampal and raphe nuclei 5-HT1AR with severe CA compared with mild/moderate CA and HVs. Results: There was a group-by-region effect (p = 0.011) when considering HV, depressive episode mild/moderate CA, and depressive episode severe CA groups, driven by significantly higher hippocampal 5-HT1AR binding potential in participants in a depressive episode with severe CA relative to HVs (p = 0.019). Contrary to our hypothesis, no significant binding potential differences were detected in the raphe nuclei (p-values > 0.05). Conclusions: With replication in larger samples, elevated hippocampal 5-HT1AR binding potential may serve as a promising biomarker through which to investigate the neurobiological link between CA and depression.
- 24 January 2023
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 66 (1) , 1-21
Open AccessIn vivo serotonin 1A receptor hippocampal binding potential in depression and reported childhood adversity
Background: Reported childhood adversity (CA) is associated with development of depression in adulthood and predicts a more severe course of illness. Although elevated serotonin 1A receptor (5-HT1AR) binding potential, especially in the raphe nuclei, has been shown to be a trait associated with major depression, we did not replicate this finding in an independent sample using the partial agonist positron emission tomography tracer [11C]CUMI-101. Evidence suggests that CA can induce long-lasting changes in expression of 5-HT1AR, and thus, a history of CA may explain the disparate findings. Methods: Following up on our initial report, 28 unmedicated participants in a current depressive episode (bipolar n = 16, unipolar n = 12) and 19 non-depressed healthy volunteers (HVs) underwent [11C]CUMI-101 imaging to quantify 5-HT1AR binding potential. Participants in a depressive episode were stratified into mild/moderate and severe CA groups via the Childhood Trauma Questionnaire. We hypothesized higher hippocampal and raphe nuclei 5-HT1AR with severe CA compared with mild/moderate CA and HVs. Results: There was a group-by-region effect (p = 0.011) when considering HV, depressive episode mild/moderate CA, and depressive episode severe CA groups, driven by significantly higher hippocampal 5-HT1AR binding potential in participants in a depressive episode with severe CA relative to HVs (p = 0.019). Contrary to our hypothesis, no significant binding potential differences were detected in the raphe nuclei (p-values > 0.05). Conclusions: With replication in larger samples, elevated hippocampal 5-HT1AR binding potential may serve as a promising biomarker through which to investigate the neurobiological link between CA and depression.
- 29 April 2022
- Published by Springer Nature in Molecular Psychiatry
- Vol. 27 (8) , 3417-3424
Serotonin transporter binding in major depressive disorder: impact of serotonin system anatomy
Serotonin transporter (5-HTT) binding deficits are reported in major depressive disorder (MDD). However, most studies have not considered serotonin system anatomy when parcellating brain regions of interest (ROIs). We now investigate 5-HTT binding in MDD in two novel ways: (1) use of a 5-HTT tract-based analysis examining binding along serotonergic axons; and (2) using the Copenhagen University Hospital Neurobiology Research Unit (NRU) 5-HT Atlas, based on brain-wide binding patterns of multiple serotonin receptor types. [11C]DASB 5-HTT PET scans were obtained in 60 unmedicated participants with MDD in a current depressive episode and 31 healthy volunteers (HVs). Binding potential (BPP) was quantified with empirical Bayesian estimation in graphical analysis (EBEGA). Within the [11C]DASB tract, the MDD group showed significantly lower BPP compared with HVs (p = 0.02). This BPP diagnosis difference also significantly varied by tract location (p = 0.02), with the strongest MDD binding deficit most proximal to brainstem raphe nuclei. NRU 5-HT Atlas ROIs showed a BPP diagnosis difference that varied by region (p < 0.001). BPP was lower in MDD in 3/10 regions (p-values < 0.05). Neither [11C]DASB tract or NRU 5-HT Atlas BPP correlated with depression severity, suicidal ideation, suicide attempt history, or antidepressant medication exposure. Future studies are needed to determine the causes of this deficit in 5-HTT binding being more pronounced in proximal axon segments and in only a subset of ROIs for the pathogenesis of MDD. Such regional specificity may have implications for targeting antidepressant treatment, and may extend to other serotonin-related disorders.
- 29 April 2022
- Published by Springer Nature in Molecular Psychiatry
- Vol. 27 (8) , 3417-3424
Serotonin transporter binding in major depressive disorder: impact of serotonin system anatomy
Serotonin transporter (5-HTT) binding deficits are reported in major depressive disorder (MDD). However, most studies have not considered serotonin system anatomy when parcellating brain regions of interest (ROIs). We now investigate 5-HTT binding in MDD in two novel ways: (1) use of a 5-HTT tract-based analysis examining binding along serotonergic axons; and (2) using the Copenhagen University Hospital Neurobiology Research Unit (NRU) 5-HT Atlas, based on brain-wide binding patterns of multiple serotonin receptor types. [11C]DASB 5-HTT PET scans were obtained in 60 unmedicated participants with MDD in a current depressive episode and 31 healthy volunteers (HVs). Binding potential (BPP) was quantified with empirical Bayesian estimation in graphical analysis (EBEGA). Within the [11C]DASB tract, the MDD group showed significantly lower BPP compared with HVs (p = 0.02). This BPP diagnosis difference also significantly varied by tract location (p = 0.02), with the strongest MDD binding deficit most proximal to brainstem raphe nuclei. NRU 5-HT Atlas ROIs showed a BPP diagnosis difference that varied by region (p < 0.001). BPP was lower in MDD in 3/10 regions (p-values < 0.05). Neither [11C]DASB tract or NRU 5-HT Atlas BPP correlated with depression severity, suicidal ideation, suicide attempt history, or antidepressant medication exposure. Future studies are needed to determine the causes of this deficit in 5-HTT binding being more pronounced in proximal axon segments and in only a subset of ROIs for the pathogenesis of MDD. Such regional specificity may have implications for targeting antidepressant treatment, and may extend to other serotonin-related disorders.
- Open Access
- 10 January 2022
- Published by Elsevier in NeuroImage
- Vol. 249, 118901
Source‐to‐Target Automatic Rotating Estimation (STARE) – A publicly‐available, blood‐free quantification approach for PET tracers with irreversible kinetics: Theoretical framework and validation for [18F]FDG
- 10 January 2022
- Published by Elsevier in NeuroImage
- Vol. 249, 118901
Open AccessSource‐to‐Target Automatic Rotating Estimation (STARE) – A publicly‐available, blood‐free quantification approach for PET tracers with irreversible kinetics: Theoretical framework and validation for [18F]FDG
- Open Access
- 16 September 2021
- Published by Center for Open Science in PsyArXiv
Serotonin Transporter Binding in Major Depressive Disorder: Impact of Serotonin System Anatomy
Serotonin transporter (5-HTT) binding deficits are reported in major depressive disorder (MDD). However, most studies have not considered serotonin system anatomy when parcellating brain regions of interest (ROIs). We now investigate 5-HTT binding in MDD in two novel ways: (1) use of a 5-HTT tract-based analysis examining binding along serotonergic axons; and (2) using the Copenhagen University Hospital Neurobiology Research Unit (NRU) 5-HT Atlas, based on brain-wide binding patterns of multiple serotonin receptor types. [11C]DASB 5-HTT PET scans were obtained in 59 unmedicated participants with MDD in a current depressive episode and 32 healthy volunteers (HVs). Binding potential (BPP) was quantified with empirical Bayesian estimation in graphical analysis (EBEGA). Within the [11C]DASB tract, MDD showed significantly lower BPP compared with HVs (p=0.02). The BPP diagnosis difference varied by tract location at a trend-level (p=0.08), with MDD binding deficit strongest most proximal to brainstem raphe nuclei. NRU 5-HT Atlas ROIs showed trend-level lower BPPin MDD relative to HVs (p=0.06) and BPP diagnosis difference that varied by region (p=0.001). BPP was lower in MDD in 4/10 regions (p-values<0.05). Neither [11C]DASB tract or NRU 5-HT Atlas BPP correlated with depression severity, suicidal ideation or suicide attempt history. Future studies are needed to determine the causes of this deficit in 5-HTT binding being more pronounced in proximal axon segments and in only a subset of ROIs for the pathogenesis of MDD. Such regional specificity may have implications for targeting antidepressant treatment, and may extend to other serotonin-related disorders.
- 16 September 2021
- Published by Center for Open Science in PsyArXiv
Open AccessSerotonin Transporter Binding in Major Depressive Disorder: Impact of Serotonin System Anatomy
Serotonin transporter (5-HTT) binding deficits are reported in major depressive disorder (MDD). However, most studies have not considered serotonin system anatomy when parcellating brain regions of interest (ROIs). We now investigate 5-HTT binding in MDD in two novel ways: (1) use of a 5-HTT tract-based analysis examining binding along serotonergic axons; and (2) using the Copenhagen University Hospital Neurobiology Research Unit (NRU) 5-HT Atlas, based on brain-wide binding patterns of multiple serotonin receptor types. [11C]DASB 5-HTT PET scans were obtained in 59 unmedicated participants with MDD in a current depressive episode and 32 healthy volunteers (HVs). Binding potential (BPP) was quantified with empirical Bayesian estimation in graphical analysis (EBEGA). Within the [11C]DASB tract, MDD showed significantly lower BPP compared with HVs (p=0.02). The BPP diagnosis difference varied by tract location at a trend-level (p=0.08), with MDD binding deficit strongest most proximal to brainstem raphe nuclei. NRU 5-HT Atlas ROIs showed trend-level lower BPPin MDD relative to HVs (p=0.06) and BPP diagnosis difference that varied by region (p=0.001). BPP was lower in MDD in 4/10 regions (p-values<0.05). Neither [11C]DASB tract or NRU 5-HT Atlas BPP correlated with depression severity, suicidal ideation or suicide attempt history. Future studies are needed to determine the causes of this deficit in 5-HTT binding being more pronounced in proximal axon segments and in only a subset of ROIs for the pathogenesis of MDD. Such regional specificity may have implications for targeting antidepressant treatment, and may extend to other serotonin-related disorders.
- Open Access
Source-to-Target Automatic Rotating Estimation (STARE) – a publicly-available, blood-free quantification approach for PET tracers with irreversible kinetics: Theoretical framework and validation for [ 18 F]FDG
Introduction: Full quantification of positron emission tomography (PET) data requires an input function. This generally means arterial blood sampling, which is invasive, labor-intensive and burdensome. There is no current, standardized method to fully quantify PET radiotracers with irreversible kinetics in the absence of blood data. Here, we present Source-to-Target Automatic Rotating Estimation (STARE), a novel, data-driven approach to quantify the net influx rate (K i ) of irreversible PET radiotracers, that requires only individual-level PET data and no blood data. We validate STARE with [ 18 F]FDG PET and assess its performance using simulations. Methods: STARE builds upon a source-to-target tissue model, where the tracer time activity curves (TACs) in multiple “target” regions are expressed at once as a function of a “source” region, based on the two-tissue irreversible compartment model, and separates target region K i from source K i by fitting the source-to-target model across all target regions simultaneously. To ensure identifiability, data-driven, subject-specific anchoring is used in the STARE minimization, which takes advantage of the PET signal in a vasculature cluster in the FOV that is automatically extracted and partial volume-corrected. To avoid the need for any a priori determination of a single source region, each of the considered regions acts in turn as the source, and a final K i is estimated in each region by averaging the estimates obtained in each source rotation. Results: In a large dataset of [ 18 F]FDG human scans (N=69), STARE K i estimates were in good agreement with corresponding arterial blood-based estimates (regression slope=0.88, r=0.80), and were precisely estimated, as assessed by comparing STARE K i estimates across several runs of the algorithm (coefficient of variation across runs=6.74 ± 2.48%). In simulations, STARE K i estimates were largely robust to factors that influence the individualized anchoring used within its algorithm. Conclusion: Through simulations and application to [ 18 F]FDG PET data, feasibility is demonstrated for STARE blood-free, data-driven quantification of K i . Future work will include applying STARE to PET data obtained with a portable PET camera and to other irreversible radiotracers.
Open AccessSource-to-Target Automatic Rotating Estimation (STARE) – a publicly-available, blood-free quantification approach for PET tracers with irreversible kinetics: Theoretical framework and validation for [ 18 F]FDG
Introduction: Full quantification of positron emission tomography (PET) data requires an input function. This generally means arterial blood sampling, which is invasive, labor-intensive and burdensome. There is no current, standardized method to fully quantify PET radiotracers with irreversible kinetics in the absence of blood data. Here, we present Source-to-Target Automatic Rotating Estimation (STARE), a novel, data-driven approach to quantify the net influx rate (K i ) of irreversible PET radiotracers, that requires only individual-level PET data and no blood data. We validate STARE with [ 18 F]FDG PET and assess its performance using simulations. Methods: STARE builds upon a source-to-target tissue model, where the tracer time activity curves (TACs) in multiple “target” regions are expressed at once as a function of a “source” region, based on the two-tissue irreversible compartment model, and separates target region K i from source K i by fitting the source-to-target model across all target regions simultaneously. To ensure identifiability, data-driven, subject-specific anchoring is used in the STARE minimization, which takes advantage of the PET signal in a vasculature cluster in the FOV that is automatically extracted and partial volume-corrected. To avoid the need for any a priori determination of a single source region, each of the considered regions acts in turn as the source, and a final K i is estimated in each region by averaging the estimates obtained in each source rotation. Results: In a large dataset of [ 18 F]FDG human scans (N=69), STARE K i estimates were in good agreement with corresponding arterial blood-based estimates (regression slope=0.88, r=0.80), and were precisely estimated, as assessed by comparing STARE K i estimates across several runs of the algorithm (coefficient of variation across runs=6.74 ± 2.48%). In simulations, STARE K i estimates were largely robust to factors that influence the individualized anchoring used within its algorithm. Conclusion: Through simulations and application to [ 18 F]FDG PET data, feasibility is demonstrated for STARE blood-free, data-driven quantification of K i . Future work will include applying STARE to PET data obtained with a portable PET camera and to other irreversible radiotracers.
- Open Access
- 30 June 2021
- Published by Elsevier in Brain, Behavior, & Immunity - Health
- Vol. 16, 100287
Neuroinflammation in World Trade Center responders at midlife: A pilot study using [18F]-FEPPA PET imaging
- 30 June 2021
- Published by Elsevier in Brain, Behavior, & Immunity - Health
- Vol. 16, 100287
Open AccessNeuroinflammation in World Trade Center responders at midlife: A pilot study using [18F]-FEPPA PET imaging